Evidence map›Paper›PMID 30458856›Full record

ReviewBreast cancer research : BCR2018

Statin drugs to reduce breast cancer recurrence and mortality.

Colin H Beckwitt, Adam Brufsky, Zoltán N Oltvai, Alan Wells

Registry-linked trialOpen access · goldFull text readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Breast cancer research : BCR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03971019 (Survival Benefits of Statins in Breast Cancer Patients With Abnormal Lipid Metabolism), which is not on this map. Cited by 109 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 6 pooled it
6.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03971019 phase3unknown statusnot on this mapstarted 2019, after this paper: background citation

Survival Benefits of Statins in Breast Cancer Patients With Abnormal Lipid Metabolism

TypeinterventionalSponsorPeking Union Medical College HospitalRan2019 to 2024Enrolled314ConditionsBreast Cancer FemaleArmsstatins, Dietary intervention group (control group)
3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 6 syntheses or guidelines pooled it, 197 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Colin H BeckwittDepartment of Pathology, University of Pittsburgh, Pittsburgh, 15231, PA, USA.
Adam BrufskyMagee-Women's Hospital of Pittsburgh, 300 Halket St., Pittsburgh, 15213, PA, USA.
Zoltán N OltvaiDepartment of Pathology, University of Pittsburgh, Pittsburgh, 15231, PA, USA.
Alan WellsDepartment of Pathology, University of Pittsburgh, Pittsburgh, 15231, PA, USA. wellsa@upmc.edu.ORCID 0000-0002-1637-8150
University of Pittsburgh · USMagee-Womens Hospital · US

Funding

Probing the Role of the Tumor Microenvironment on Mechanistic Biomarkers for Chemotherapeutic ResistanceUH3TR000496 · NCATS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GRIFFITH, LINDA G · 2014 to 2016
$3.5M
All-Human Microphysical Model of Metastasis TherapyUH2TR000496 · NCATS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GRIFFITH, LINDA G · 2012 to 2013
$2.3M
Oxygen impact on tumor metastasis dormancy and therapyF30CA199947 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BECKWITT, COLIN HENRY · 2016 to 2018
$142k
BLRD VA I01 BX003368NCATS NIH HHS UH2 TR000496NCATS NIH HHS UH3 TR000496NCI NIH HHS CA199947NCI NIH HHS F30 CA199947
6 · The paper itself

Abstract

Epidemiologic studies have, variably, shown the concomitant use of statin drugs to be beneficial to cancer outcomes. Statin drugs have been FDA approved for three decades for the treatment of high cholesterol and atherosclerotic coronary artery disease and are widely used. This has engendered studies as to their influence on concomitant diseases, including cancers. In this context, statin use has been correlated, variably, with a decrease in deaths from breast cancer. However, there is no extant model for this effect, and the extent of efficacy is open to question.The overarching goal of this article is to communicate to the reader of the potential of statins to reduce breast cancer progression and mortality. This is the use as a secondary prevention measure, and not as a therapy to directly counter active cancer. First, salient aspects of statin pharmacology, as relates to cardiovascular disease, will be discussed. Second, the basic and clinical research studies that investigate statin usage in breast cancer will be presented. Additionally, statin effects in other cancer types will be included for context. Finally, proposals for future basic and clinical research studies to determine the role of statins in breast cancer management will be presented.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCardiovascular DiseasesClinical Trials as TopicComorbidityDisease ProgressionFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIncidenceNeoplasm Recurrence, LocalTreatment OutcomeHydroxymethylglutaryl-CoA Reductase InhibitorsBreast cancerLipophilicityMetastasisPrenylationSecondary preventionStatins

Identifiers

PMID30458856
PMCPMC6247616
OpenAlexW2901206497

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.